Form SC 13G/A RAPT Therapeutics, Inc. Filed by: FMR LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)
November 12, 2024 4:08 PM ESTLeerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).
The analyst comments "Bottom Line: RAPT reported 3Q24 financial results following the company's decision to terminate development of zelnecirnon (RPT193, oral CCR4 antagonist) based on recent FDA feedback suggesting there was no viable path forward for this program (see our note HERE).... More
Stifel Downgrades Rapt Therapeutics (RAPT) to Hold
November 12, 2024 4:04 PM ESTStifel analyst Alex Thompson downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Hold with a price target of $2.00 (from $7.00).
The analyst comments "We are downgrading RAPT to Hold following the recent Zelnecirnon program termination (LINK). RAPT discontinued the program following FDA feedback suggesting... More
